Analysis of the first therapeutic-target-achieving time of warfarin therapy and associated factors in patients with pulmonary embolism

Abstract

Abstract. The present study aimed to investigate the factors affecting the first therapeutic-target-achieving (TTA) time of warfarin therapy in patients with acute pulmonary embolism (PTE). Between January 2008 and June 2013, patients with PTE confirmed by transpulmonary arterial enhanced computed tomographic pulmonary angiography or pulmonary ventilation perfusion scanning were included in the present study. Data collected included demographic information, history of tobacco and alcohol intake, basic diseases (stable and unstable hypertension, diabetes, heart failure, cancer/cerebral infarction, old myocardial infarction and atrial fibrillation), liver and kidney function, the haemoglobin and platelet count of the blood, international normalized ratio monitoring, warfarin dosage adjustment and medication combinations. Dynamic changes in international normalized ratio, anticoagulant efficacy, and adverse events within 90 days were monitored and analyzed. Univariate analysis demonstrated that the following factors affect the first TTA time: Initial dose, body mass index (BMI), liver function, heart failure, and the administration of levofloxacin, cephalosporins, and blood circulation-activating drugs. Logistic regression analysis revealed that the following were independent factors of the first TTA time: Initial dose, BMI, liver function, heart failure and levofloxacin. Therefore, the results of the present study demonstrated that various factors may affect the first TTA time of warfarin therapy, including the initial dose, BMI, liver function, heart function and concomitant medication.

Ultrasound-triggered herceptin liposomes for breast cancer therapy

“…SDDSs are nanostructures capable of reducing drug side effects, increasing blood circulation time, and increasing drug concentrations at target sites, thus ensuring better patient compliance 26 , 27 . SDDSs release their payloads at target sites in response to internal or external triggers such as temperature, pH, enzymes, light, mechanical waves (e.g., ultrasound) or magnetic fields 28 – 32 . Several nanostructured delivery systems have been studied for cancer treatment, such as liposomes, solid lipid nanoparticles, metal organic frameworks, micelles, carbon nanostructures, dendrimers, quantum dots and antibody–drug conjugates (ADCs) 33 .…”

Ultrasound-triggered Release of Calcein and Doxorubicin from HER2-targeted Liposomes in Breast Cancer Therapy

“…SDDSs are nanostructures capable of reducing drug side effects, increasing blood circulation time, and increasing drug concentrations at target sites, thus ensuring better patient compliance 19,20 . SDDSs release their payloads at target sites in response to internal or external triggers such as temperature, pH, enzymes, light, mechanical waves (e.g., ultrasound) or magnetic elds [21][22][23][24][25] . Several nanostructured delivery systems have been studied for cancer treatment, such as liposomes, solid lipid nanoparticles, metal organic frameworks, micelles, dendrimers, and quantum dots 26 .…”